Managing Development of COVID-19 Vaccines in 2021 and Beyond

Plenary webinar and panel discussion

The impact of COVID-19 has had an unprecedented impact on the world economy devastating many industries and lives. Thankfully, through the advancement of science driving the development of COVID-19 treatments, vaccines and diagnostics, a glimmer of hope now exists.

This plenary panel discussion is part of a webinar series “Advancing COVID-19 Trials” hosted by IQVIA. We aim to explore the evolving science and strategy to manage the development of COVID-19 vaccines in 2021 and beyond.

To learn more, download presentation slides or watch recorded presentation.

Plenary Webinar Overview

  • During this on-demand webinar and panel discussion, our industry experts engage in dialogue on how we will overcome challenges in developing the much-needed next wave of COVID-19 vaccines.
  • What are the challenges in getting the current COVID-19 vaccine front runners to the market?
  • Why are new vaccines needed even after the successful launch of the front running vaccines?
  • How will herd immunity play into planning? 
  • What is the latest thinking on the immunology behind the body’s response to SARS-CoV-2? What strategies can be used to prove and measure an immune response to SARS-CoV-2? 
  • What types of study designs will be employed? What are the recommendations from the various regulatory and scientific bodies? How will immune correlates be used?


Patrice HugoPatrice Hugo, Ph.D
Chief Scientific Officer
Q2 Solutions

Dr. Patrice Hugo, Chief Scientific Officer at Q2 Solutions, leads the global scientific strategy and is responsible for the medical affairs and scientific activities for the Central Laboratories, and Specialty Testing Centers of Excellence worldwide including the Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Prior to joining Q2 Solutions, Dr. Hugo was Associate Vice President and Chief Clinical Trial Scientist at LabCorp/Covance Central Lab Division and Chief Scientific Officer at Clearstone Central Lab acquired by LabCorp. Previously, he worked at Caprion as EVP R&D, and Principal Investigator at the Montreal Clinical Research Institute with academic affiliation at McGill University. Dr. Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and held post-doctoral positions at the Walter and Eliza Hall Institute, Australia, and the Howard Hughes Medical Institute, USA. He is author or co-author of over 75 scientific manuscripts and has over 25 years of biomarker experience. He also played an active role in several industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).

Bob Bailer, Ph.D
Senior Director, Vaccines
Q2 Solutions

Dr. Robert Bailer is the senior director of Vaccines at Q2 Solutions. In this role he oversees all aspects of the immunogenicity testing of vaccine products inclusive of the full assay life cycle from R&D through clinical testing. The range of assays in our Vaccine franchise spans PCR, antibody binding, and functional assays such as viral neutralization. Dr. Bailer has over 25 years of experience in the areas of viral immunology and vaccines. Most recently he served as the Director of the Immunogenicity Testing Laboratory at the NIH/NIAID/Vaccine Research Center for over 17 years. In this role he oversaw the immunogenicity testing for all VRC clinical trials of vaccine and broadly neutralizing antibodies. Dr. Bailer has in excess of 120 peer-reviewed publications.

Dr. Ken Lee
Chief Medical Officer, Asia Pacific, Head - Real World, MedTech and Contract Sales & Medical Solutions

Dr. Ken Lee is Chief Medical Officer (CMO) Asia Pacific at IQVIA based in Singapore. Ken is a physician by training, acquiring a MBBS degree from the University of Melbourne. He worked as a clinician in both Australia and Malaysia before joining industry. In his current role, he is overall responsible for the safety and ethics of IQVIA clinical development projects in the Asia Pacific Region. In addition, Ken also leads the Medical Advisors/Directors, Contract Sales & Medical Solutions and Real World Solutions businesses for IQVIA in the Asia Pacific Region.

Prior to IQVIA, Ken held positions in sales and marketing, medical affairs and clinical development over a 10+ year career within the pharmaceutical industry with multinational organizations Bayer, UCB, Aventis and Sanofi-Synthelabo. Ken has worked in both local operational and regional/global strategic positions while being based in a number of countries including China, Malaysia, Singapore, Taiwan, Germany and Australia. His experience covers a broad range of therapy areas, and in particular, oncology and central nervous system disorders. He has at various times covered Asia Pacific, Japan, Europe, Canada, Russia, Africa and the Middle East.

Dr. Paul Turner
Global Head of Medical Strategy, Infectious Diseases and Vaccines

Dr. Paul Turner is a Senior Medical Director and Global Head of Medical Strategy in the Infectious Diseases & Vaccines (IDV) Center of Excellence at IQVIA. He is board certified in Internal Medicine and Infectious Diseases and holds an active medical license in California.

Dr. Turner is currently the physician / subject matter expert for IQVIA’s response to the COVID-19 outbreak. In this role he has been advising companies both large and small on design of both vaccine and treatment trials for this unprecedented pandemic. As head of the IDV Center of Excellence, he is able to leverage additional IQVIA assets including Strategic Drug Development, Virtual and Hybrid trial design, Asia Pacific regulatory experts and our IDV Biostats group.

Paul has served as a medical and scientific advisor and safety physician on multiple clinical trials in the following indications: HIV, influenza vaccines, West Nile Virus vaccines, Hepatitis B and C, invasive fungal diseases, plague vaccines, anthrax vaccines, dengue vaccines, RSV treatment and vaccines.